Breaking News
February 20, 2018 - Safe sleep recommendations for parents that may help reduce child’s risk of SUID
February 20, 2018 - Why Do So Few Docs Have Buprenorphine Waivers?
February 20, 2018 - Low levels of alcohol good for the brain
February 20, 2018 - Experimental treatment improves invisible symptoms of a man with spinal cord injury
February 20, 2018 - Myriad’s EndoPredict offers better prediction of breast cancer recurrence, analysis shows
February 20, 2018 - Researchers identify fifteen genes that determine our facial features
February 20, 2018 - Morning Break: New Health IT Player; Luxturna No Bargain; Nuclear Freakout
February 20, 2018 - How does it compare? Hospice care at home, at assisted living facility, at nursing home
February 19, 2018 - Scientists develop water-soluble warped nanographene for bioimaging
February 19, 2018 - It’s Not Your Imagination: You’re Hungrier After Losing Weight
February 19, 2018 - Antihypertensive Use At Delivery Rising in Preeclampsia
February 19, 2018 - A centuries-old math equation used to solve a modern-day genetics challenge
February 19, 2018 - Liquid biopsies could be used as new predictive marker for metastatic TNBC
February 19, 2018 - Russian researchers develop new multi-layered biodegradable scaffolds
February 19, 2018 - Are ‘Vaccine Skeptics’ Responsible for Flu Deaths?
February 19, 2018 - Hidden genetic effects behind immune diseases may be missed, study suggests
February 19, 2018 - Emergency nurses experience regular verbal and physical abuse
February 19, 2018 - Study sheds light on biology that guides behavior across different stages of life
February 19, 2018 - Morning Break: Transgender Breast Feeding; Brazilian ‘Pro-Vaxxers’; Post-Stroke Exercise
February 19, 2018 - Meningitis vaccination strategy in Africa found to be effective, economical
February 19, 2018 - Researchers uncover how excess calcium may influence development of Parkinson’s disease
February 19, 2018 - Psoriasis drug also effective at reducing aortic inflammation
February 19, 2018 - Excess emissions can make serious contributions to air pollution, study shows
February 19, 2018 - Researchers reveal potential biological roots behind individuality
February 19, 2018 - Diabetes Drugs Differ on HF; School-Based Obesity Program Flop; Plaque Type in ACS
February 19, 2018 - Surgical infections linked to drug-resistant bugs, study suggests
February 19, 2018 - Poor awareness may hinder a child’s early dental care
February 19, 2018 - Research finds rising trend in incidence of merkel cell carcinoma
February 19, 2018 - Researchers uncover Ras protein’s role in uncontrolled cancer growth
February 19, 2018 - FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer
February 19, 2018 - Educational Tool Boosts Cervical Length Screening
February 19, 2018 - Spider’s web inspires removable implant that may control type 1 diabetes
February 19, 2018 - Scientists develop fluorescent probe to identify cancer stem cells
February 19, 2018 - University Hospital of Santiago de Compostela participates in large pancreatic cancer study
February 19, 2018 - New blood test shows promise to revolutionize diagnosis of tick-borne diseases
February 19, 2018 - Report: Use, Not Price, Drives State Health Costs
February 19, 2018 - Emergency services crews often unprepared for diabetic crises
February 19, 2018 - Scientists in Sweden create DNA nanowires that offer hope for treatment of diseases
February 19, 2018 - ID Break: Clean Hands, Fewer Abx; $11 Million HIV Cure?; MenB Vax for Kids
February 19, 2018 - Patient exposure to X-rays depends on how dentists are paid
February 19, 2018 - Study reveals parents’ views toward children’s tanning bed use
February 19, 2018 - Shot may help reduce risk of shingles
February 19, 2018 - FDA approves first treatment to reduce risk of NSCLC progression
February 19, 2018 - FDA Expands Approval of Imfinzi (durvalumab) to Reduce the Risk of Non-Small Cell Lung Cancer Progressing
February 19, 2018 - D.C. Week: Congress Passes Spending Bill
February 19, 2018 - Heart-muscle patches made with human cells improve heart attack recovery
February 19, 2018 - FDA Approves First Blood Test to Detect Concussions
February 19, 2018 - Survival Bump in Bladder Cancer with Keytruda
February 18, 2018 - Scientists describe the mechanism of heart regeneration in the zebrafish
February 18, 2018 - Scientists uncover the structure of microtubule motor proteins
February 18, 2018 - Light-activated cancer drugs without toxic side effects are closer to becoming reality
February 18, 2018 - Pioneering research could provide novel insight into how genomic information is read
February 18, 2018 - Pearls From: David Putrino, PhD
February 18, 2018 - Researchers uncover how cancer stem cells drive triple-negative breast cancer
February 18, 2018 - Morning Break: Anti-Anti-Vaxxers; Private Piercings Prohibited; A Case for Pelvic Massage
February 18, 2018 - Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo
February 18, 2018 - Specialist residential service for adults with autism opens in Swansea
February 18, 2018 - FDA Moves to Limit Loperamide Doses per Package
February 18, 2018 - Alcohol use disorder – Genetics Home Reference
February 18, 2018 - Autism might be better detected using new two-minute questionnaire
February 18, 2018 - Hand hygiene-intervention practices may reduce risk of infection among nursing home patients
February 18, 2018 - Researchers develop most sophisticated mini-livers to date
February 18, 2018 - Obamacare Helped More Young Women Get Prenatal Care: Study
February 18, 2018 - School-Based Program Fails to Dent Kids’ Obesity
February 18, 2018 - Research compares neural activity in children with and without autism spectrum disorder
February 18, 2018 - Poor fitness levels increase the risk dementia, concludes study
February 18, 2018 - Risk Score May Reveal if Kids are Victims of Ill-Treatment
February 18, 2018 - Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects
February 18, 2018 - Acute treatment suppresses posttraumatic arthritis in ankle injury
February 18, 2018 - A Role for Budesonide in Autoimmune Hepatitis?
February 18, 2018 - Lupus patients exhibit altered cell proteins, a discovery with potential implications for diagnostics
February 18, 2018 - Muscle plays vital role in regulating heat loss from the hands
February 18, 2018 - High-tech brain scans can provide new way to define intelligence
February 18, 2018 - Study reveals the association between ultra-processed foods and cancer
February 18, 2018 - Prescription Opioid Use Tied to Higher Pneumonia Risk
February 18, 2018 - A non-invasive method to detect Alzheimer’s disease
February 18, 2018 - Deletion of specific enzyme leads to improvement in memory and cognitive functions
February 18, 2018 - Amyloid protein may be transmitted through neurosurgical instruments, study suggests
February 18, 2018 - Electric brain signals of males and females show differences
February 18, 2018 - American Heart Association commends McDonald’s for offering healthier menu in kids’ meals
Stop-Smoking Drug May Also Help with Excessive Boozing

Stop-Smoking Drug May Also Help with Excessive Boozing

image_pdfDownload PDFimage_print

Action Points

  • Treatment with the nicotine-dependence drug varenicline (Chantix), along with medical management, was associated with reductions in heavy drinking among male, but not female, smokers with comorbid alcohol-use disorder.
  • Note that the finding of a smoking-cessation benefit with varenicline in participants who reported little motivation to quit raises important questions about the current practice of offering treatment only to smokers who express a desire to give up cigarettes.

Treatment with the nicotine-dependence drug varenicline (Chantix), along with medical management, was associated with modest reductions in heavy drinking among male smokers with comorbid alcohol-use disorder in a small randomized trial.

Men — but not women — in the placebo-controlled study showed a small benefit from varenicline in heavy drinking measures, Stephanie O’Malley, PhD, of Yale School of Medicine in New Haven, Connecticut, and colleagues reported in JAMA Psychiatry.

The 131 participants were all active smokers. Although they were not seeking and were not provided smoking-cessation counseling during the study, 13% in the varenicline group were not smoking at the end of the trial, while none of those randomized to the placebo arm of the study had quit smoking.

O’Malley said this finding has implications for the future use of varenicline and other smoking-cessation therapies, which are typically offered in the primary care setting exclusively to patients who say they are ready to give up tobacco products.

“This suggests that first-line medications designed to help people quit smoking should be offered to patients, even if they are not ready to quit,” she told MedPage Today.

“Individuals who reduce their drinking have greater success quitting smoking, and individuals who quit smoking are more likely to maintain long-term alcohol abstinence,” she said. “Further, treatment is more cost-effective when both behaviors are addressed. Treating one behavior without addressing the co-morbid condition reduces the effectiveness of the intervention.”

O’Malley said the current study is not the first to evaluate varenicline as a treatment for alcohol abuse, but most prior trials enrolled both smokers and nonsmokers. The current study also included a more intensive counseling approach than most previous studies.

The phase II, placebo-controlled trial was conducted at outpatient clinics affiliated with Columbia University and Yale School of Medicine, and participants were recruited primarily through print, radio, and social media advertising, and through outreach to healthcare professionals.

Eligible participants met alcohol-dependence criteria and reported heavy drinking (five or more drinks for men and four or more drinks for women) two or more times per week and smoking two or more times per week.

The 131 participants were randomized to treatment with either varenicline (1 mg twice daily for 16 weeks) or placebo, stratified by sex and site. Data analysis was conducted from February 5, 2016, to September 29, 2017.

Medical management emphasized medication adherence for 4 weeks followed by support for changing drinking.

The main outcomes measured were the percentage of heavy drinking days during weeks 9 to 16, no heavy drinking days during weeks 9 to 16, and prolonged smoking abstinence during weeks 13 to 16.

About 30% of study participants were women. Mean age was 42 and about half identified themselves as black.

Thirteen of 45 men (29%) had no heavy drinking days while taking varenicline, compared with three of 47 men (6%) taking placebo. Just one of the 19 women (5%) taking varenicline had no heavy drinking days, compared with five of 20 (25%) taking placebo.

O’Malley said the failure to show an advantage for active treatment in women could be due to the relatively small number of females recruited for the trial, as well as gender differences in alcohol and nicotine dependence. Women in the study were also more likely than men to have their dosage of varenicline reduced.

“Each of these factors may have contributed to the findings, and for these reasons we cannot draw firm conclusions about the effect of varenicline in women,” she said.

In an accompanying editorial, A. Eden Evins, MD, and John F. Kelly, PhD, of Harvard Medical School and Massachusetts General Hospital Center for Addiction Medicine in Boston, wrote that while more study of the observed gender difference is needed, “the findings are consistent with the lack of evidence that medication has anti-craving or anti-relapse effects on alcohol use by alcohol-addicted women and reports that men and women respond differently to commonly sought interventions or mechanisms such as Alcoholics Anonymous.”

Nevertheless, the editorial writers also found that it may be premature to conclude that varenicline is not effective for reducing heavy drinking in women. They suggested the trial may have been underpowered for more definitive conclusions, in part because of exclusion criteria that ended up rejecting more than two-thirds of those screened. “Replication with larger samples is warranted in this intriguing line of investigation,” they wrote.

Evins and Kelly noted that the finding of a smoking-cessation benefit with varenicline in participants who reported little motivation to quit raises important questions about the current practice of offering treatment only to smokers who express a desire to give up cigarettes.

“As treatment professionals, we do not reserve pharmacotherapy for hypertension or type 2 diabetes for people who are ready to make diet and exercise changes. That analogy is not perfect, but effective pharmacotherapeutic smoking cessation aids have been extensively shown to be well tolerated and can reduce craving, withdrawal symptoms, and reward from smoking to such an extent that they can prompt smoking-cessation attempts in smokers who are not able to commit to a cessation attempt prior to treatment.”

Funding for the study was provided by the National Institutes of Health and the State of Connecticut Department of Mental Health and Addiction Services.

O’Malley reported financial relationships with Pfizer, Alkermes, Amygdala, Arkeo, Cerecor, Mitsubishi Tanabe, Opiant; being a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which is supported by Abbott, Amygdala, Ethypharm, Lilly, Lundbeck, Otsuka, Pfizer, Arbor Pharmaceuticals, and Indivior; a co-investigator on studies receiving donated medications from AstraZeneca and Novartis; and a scientific panel member for Hazelden Foundation.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles